AudioCure Pharma GmbH

AudioCure Pharma's AC102 Shows Promise in Treating Sudden Hearing Loss

7 months ago

• AudioCure Pharma has reached a milestone, enrolling over 50% of patients in its Phase 2 trial of AC102 for sudden hearing loss. • AC102 targets sensory cells and synaptic connections in the inner ear, offering a novel approach compared to non-specific corticoid treatments. • Preclinical studies demonstrated AC102's ability to restore hearing almost completely in an acoustic trauma model, highlighting its potential. • The Phase 2 trial is ongoing across several European centers and is expected to continue enrolling patients until the end of 2025.